CSPC Pharmaceutical Group (01093.HK): Phase III clinical trial of Prusogliptin Tablets combined with Dapagliflozin Tablets and Metformin Hydrochloride Extended-Release Tablets for the treatment of type 2 diabetes achieves positive topline results

Zhitong Finance APP news, CSPC Pharmaceutical Group (01093.HK) announced that the Phase III clinical trial of Prusogliptin Tablets (the product) developed by the Group in patients with type 2 diabetes mellitus (T2DM) receiving triple combination therapy of Prusogliptin, Dapagliflozin and Metformin has recently obtained topline analysis data.